N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide
C21H25ClN4O2 — CID 118075021
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide
N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide (PubChem CID 118075021) has the molecular formula C21H25ClN4O2 and a molecular weight of 400.91 g/mol. Its IUPAC name is N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide.
Molecular Properties
| Compound Name | N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide |
|---|---|
| PubChem CID | 118075021 |
| Molecular Formula | C21H25ClN4O2 |
| Molecular Weight | 400.91 g/mol |
| Exact Mass | 400.17 |
| IUPAC Name | N-[1-[5-chloro-4-(3-methyl-2-pyridinyl)-2-pyridinyl]piperidin-4-yl]-2-(1-hydroxycyclopropyl)acetamide |
| SMILES | Cc1cccnc1-c1cc(N2CCC(NC(=O)CC3(O)CC3)CC2)ncc1Cl |
| InChI | InChI=1S/C21H25ClN4O2/c1-14-3-2-8-23-20(14)16-11-18(24-13-17(16)22)26-9-4-15(5-10-26)25-19(27)12-21(28)6-7-21/h2-3,8,11,13,15,28H,4-7,9-10,12H2,1H3,(H,25,27) |
| InChIKey | VQZOIJUPNGWRHG-UHFFFAOYSA-N |
| XLogP | 3.11 |
| TPSA | 78.35 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 400.91 |
| LogP ≤ 5 | 3.11 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118075021 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.